Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gum Tech (GUMM) -- Ignore unavailable to you. Want to Upgrade?

To: Street Walker who wrote (22)	1/27/1999 12:23:00 AM
From: sun	Read Replies (1) \| Respond to of 133

I got in for 11 1/16 last week. Holding 5k firmly. You say ...technically bullish... I say it's beautiful thing! It must be up for something... sun

To: Street Walker who wrote (22)	1/27/1999 10:41:00 PM
From: GBT	Read Replies (1) \| Respond to of 133

GUMM News ZICAM Cuts Duration of Common Cold From 10 - 14 Days to 1.5 Days New technology leads to breakthrough treatment WOODLAND HILLS, Calif., Jan. 27 /PRNewswire/ -- Five percent of the American population is waging war against the common cold at this very moment. The average adult, in fact, will catch two to five colds in 1999. Finally, there's a highly effective treatment for the common cold. In initial double- blind research, ZICAM(TM) cold remedy not only relieved and reduced the severity of cold symptoms, but also reduced the duration of the common cold from 10 - 14 days to an average of 1.5 days. ZICAM nasal gel brings welcome relief to those who suffer from the more than one billion common colds that occur in the United States each year. More than 110 million of these colds are disabling, causing approximately 300 million days of restricted activity, 60 million lost days of school and 50 million lost days of work each year. History of Cold Research Medical science has failed to find a cure for the common cold mainly because colds can be caused by more than 200 different viruses. Therefore, the standard medical paradigm of treating infectious ailments by vaccine has not been a viable option. It is known, however, that the main portal of entry of the cold virus into the body is the cell lining of the nasal cavity. In the 1980s, it was discovered that the majority of viruses responsible for the common cold used a common entry point into the human body: the nasal cell ICAM-1 receptor. It was evident that if scientists found a way to block the attachment of cold viruses to these receptors, a cure of the common cold would be at hand. Making Cold History: How ZICAM Works ZICAM works in the nasal passages, fighting the cold where it starts. Once ZICAM is applied to the nasal cavity, the active ingredients bind to the cold virus and keep the virus from attaching to the ICAM-1 receptors. Once this occurs, there is a break in the cascade of infection and the cold quickly dissipates. ZICAM's unique gel matrix maintains suspension of Zinullose(TM) ZICAM's active ingredient, in the nasal membrane. This provides constant release of Gel Tech, Inc.'s unique patent-pending ionic emulsification formula, which blocks the cold virus entry for many hours after application. "ZICAM is most effective when sprayed into the nose at the onset of the infection, reducing symptoms and the duration of the common cold," said Dr. Charles B. Hensley, chief of research and scientific affairs and executive vice president for Gel Tech. Research Initial clinical research shows that ZICAM is highly effective as a treatment for the common cold. When taken at the onset, it reduced the duration of the cold from 10 - 14 days to an average of 1.5 days. Currently, researchers at a major university are preparing to conduct a large-scale clinical trial to test the effectiveness of ZICAM as a preventative treatment. Preliminary results suggest that when used once a day during the cold season, ZICAM will effectively protect against the common cold. ZICAM is developed by and manufactured for Gel Tech, Inc. (a joint venture by BIODELIVERY Technologies, Inc., a privately-held biotechnology company, and GumTech International, Inc., a publicly-held company located in Phoenix, Ariz.). Gel Tech's mission is to develop and provide innovative products that change consumers' expectations for the over-the-counter products they need and use. For more information on ZICAM, visit Gel Tech's web site at zicam.com SOURCE Gel Tech, Inc. -0- 01/27/99 /CONTACT: Dianne Ryan, dryan@shandwick.com, or Berit Sunde, bsunde@shandwick.com, 612-832-5000, both of Shandwick International for ZICAM/ /Web site: zicam.com CO: Gel Tech, Inc.; BIODELIVERY Technologies, Inc.; GumTech International, Inc. ST: California, Arizona IN: MTC SU: PDT JW-KE -- MNW001 -- 2130 01/27/99 09:05 EST prnewswire.com :SUBJECT: CA AZ NPRD MED Copyright (c) 1999 PR Newswire